Autopsy report · NCT00202371

Transfusion Effects in Myelodysplastic Patients: Limiting Exposure

“Too few inclusions”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 4

Sponsor

Sanquin Research & Blood Bank Divisions

Sponsor type

University, hospital or other

Conditions

Myelodysplastic Syndromes

Interventions

Red Blood Cell transfusion

Participants

0

Sites

1

Countries

Netherlands

Trials that died the same way

• Pronostic Value of Endothelial Dysfunction in Heart Failure
  “Not enough inclusions” (95% match in meaning)
• Bedside Therapeutic Monitoring of β-Lactam Levels in Newborns, Children and Adolescents Admitted to Intensive Care.
  “insufficient inclusions” (88% match in meaning)
• Development of a Predictive Score for Local Complications of Femoral Bifurcation Surgery
  “lack of inclusions” (86% match in meaning)
• A Lexico-semantic Program on Tactile Tablet for Patients With Alzheimer's Disease
  “Lack of inclusion” (82% match in meaning)
• Impact of Anti-cytomegalovirus Treatment in the Management of Relapsing Ulcerative Colitis Requiring Vedolizumab Therapy
  “low of inclusions” (79% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.